ReviewFrontiers in oncology2026
The role of lysophosphatidic acid metabolism in castration-resistant prostate cancer progression.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is a leading malignancy in men, with mortality primarily attributed to progression to castration-resistant prostate cancer (CRPC). Although androgen deprivation therapy (ADT) initially demonstrates efficacy, most advanced patients eventually develop CRPC-a stage characterized by limited treatment options and poor prognosis. Elucidating the molecular mechanisms underlying CRPC transformation therefore represents a research priority. Tumor metabolic reprogramming has emerged as a hallmark of cancer, and among various metabolic pathways, lysophosphatidic acid (LPA)-a bioactive lipid mediator-has been increasingly implicated in PCa progression, particularly CRPC transformation. This review systematically examines LPA metabolic sources and signal transduction mechanisms and explores how LPA promotes CRPC progression through driving proliferation, survival, invasion, therapy resistance, and tumor microenvironment remodeling. Finally, we discuss the potential and challenges of targeting the LPA signaling pathway as a novel therapeutic strategy for CRPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.